Galmed Pharmaceuticals (GLMD)
(Delayed Data from NSDQ)
$9.35 USD
0.00 (0.00%)
Updated Sep 23, 2024 03:59 PM ET
After-Market: $9.32 -0.03 (-0.32%) 6:10 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Galmed Pharmaceuticals Ltd falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 7 | 18 | 33 | 30 | 22 |
Income After Depreciation & Amortization | -7 | -18 | -33 | -30 | -22 |
Non-Operating Income | 1 | 0 | 0 | 1 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -7 | -18 | -32 | -29 | -20 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -7 | -18 | -32 | -29 | -20 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -7 | -18 | -32 | -29 | -20 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -7 | -18 | -33 | -30 | -22 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -7 | -18 | -33 | -30 | -22 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.23 | 0.14 | 0.14 | 0.12 | 0.12 |
Diluted EPS Before Non-Recurring Items | -30.01 | -127.79 | -237.58 | -242.98 | -174.58 |
Diluted Net EPS (GAAP) | -30.01 | -127.79 | -237.58 | -242.98 | -174.58 |
Fiscal Year end for Galmed Pharmaceuticals Ltd falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 1.22 | 1.41 | 2.15 | 1.47 | 1.87 |
Income After SG&A, R&D, and Dept/Amort Expenses | -1.22 | -1.41 | -2.15 | -1.47 | -1.87 |
Non-Operating Income | 0.10 | 0.13 | 0.13 | 0.01 | 0.28 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -1.12 | -1.28 | -2.02 | -1.47 | -1.59 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -1.12 | -1.28 | -2.02 | -1.47 | -1.59 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -1.12 | -1.28 | -2.02 | -1.47 | -1.59 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 6.30 | 0.46 | 0.17 | 0.52 | 0.14 |
Diluted EPS Before Non-Recurring Items | 0.18 | -2.76 | -11.77 | -2.88 | -11.41 |
Diluted Net EPS (GAAP) | -2.16 | -2.76 | -2.64 | -2.88 | -11.40 |